Portfolio venture

BioLeonhardt

The world’s first company dedicated to total and complete heart regeneration. BioLeonhardt utilizes decades of pioneering research to reverse heart failure by converting fibrotic scar tissue back into healthy, beating muscle.

View Treatments Book a Consultation

Contact

Get in touch

(424) 291-2133

12130 Millennium Dr, Los Angeles, California, United States of America 90094

Open in Maps

/ – THE COMPANY

About this Venture

Discover our background, mission, and the world-class research driving our next-generation medical technology.

Corporate Mission & Philosophy

BioLeonhardt is the only company dedicated to total and complete heart regeneration. We believe in regenerating hearts the way they are built in the first place—with bioelectric signaling, stem cells, and a host of support agents!

Our team believes that previous heart regeneration studies with one-time injections of naked stem cells alone were woefully inadequate and not nearly enough to reverse heart failure. We believe what is needed is:

Repeat Deliveries: Daily, weekly, or monthly slow micro-pump infusion deliveries of not only muscle stem cells but a full composition of support factors (growth factors, exosomes, alkaloids, micro RNAs, nutrient hydrogel, follistatin, SDF-1, and matrix).
Bioelectric Stimulation: Stimulation of heart regeneration promoting proteins (19+) plus bioelectric real-time inflammation management.

Bioelectric Innovation: Reversing Fibrosis

BioLeonhardt uses bioelectric stimulation designed to reverse remodel failing hearts. Our patented bioelectric stimulation sequences are designed to not only stave off fibrosis but reverse it, converting previous fibrotic scar tissue into new beating, pumping muscle—even in the depths of myocardial scar tissue!

Homing & Differentiation: Patented bioelectric signal sequences for homing, proliferating, and differentiation of stem cells.
Inflammation Management: Patent-pending bioelectric signal sequences for real-time reading, managing, and modulation of inflammation—a key to recovering from advanced heart failure.
Protein Expression: Patent-pending sequences for Follistatin (the most powerful protein for muscle regeneration) and Tropoelastin (for increasing elasticity of heart muscle, the aorta, and arteries).

Unmatched Research Team Experience

Our team has established what it believes is the industry’s most comprehensive and advanced technology platform portfolio. Our history of “firsts” includes:

1988: Completed our first muscle stem cell heart regeneration studies in large animals.
1999: Published our first bioelectric regeneration paper in CIRCULATION (Journal of the American Heart Association).
2001: Led the group that completed the historic landmark first-ever non-surgical muscle stem cell repair of a human heart (published in the Journal of American College of Cardiology in 2003).

Total Regeneration Platform Strategy

BioLeonhardt is a world leader in developing innovative heart regeneration therapies. Our integrated platform includes:

Bioelectric Stimulator & Signals: Precise control of regeneration proteins and managing inflammation.
Micro Infusion Pump: Developed over 5 years with over $2 million in NSF SBIR grant support.
BL-15 Composition: A fifteen-component heart regeneration composition.
Integrated Assist: We believe results in advanced heart failure can be improved with the addition of Second Heart Assist, Inc. (www.secondheartinc.com) chronic wireless powered implant circulatory assist pumps to reduce heart workload during the 36-month regeneration course.

The Ultimate Team Alliance: All-Star Partners

BioLeonhardt is building an alliance of technology partners to build its platform:

Biomerics Advanced Catheter – Pacing infusion leads.
QIG Greatbatch – Micro stimulator OEM manufacturing.
Mettler Electronics – Benchtop stimulator OEM manufacturing.
Prizm Medical/Weartech Therapeutics – Wearable stimulators.
USTAR BioInnovations Gateway Utah – Research lab space and resources.
Cardiovascular Research and Training Institute – Pre-clinical research.
Los Angeles Biomedical Research Institute – Pre-clinical research.
CalTech (California Institute of Technology) – Research.
LABioHub – Los Angeles biomedical development resources.
BioUtah – Life sciences resources and connections.
Fluid Synchrony LLC – Micro infusion pumps.
Axolotl Biologix – Amniotic fluid supply.
Reems Lab Utah – Amniotic fluid supply.
Miron Lab Miami – PRF supply.
Chalmers Lab Santa Rosa, CA – Frequency specific microcurrent algorithms.
Trask & Britt Utah – Patent services.
Ledgergurus – Accounting services.
CapShare – Stakeholder management services.
Worthworm – Pre-money valuation services.
Asana – Project management software.
Tissue Genesis Inc. – Automated cell harvesting devices.
U.S. Stem Cell, Inc. – Manual cell harvesting kits.
UCLA Molecular Imaging Lab – Pre-clinical imaging services.
Dr. Doris Taylor Lab (Texas Heart Institute) – Research collaboration and consulting.
Dr. Stuart Williams Lab (Cardiovascular Innovation Institute) – Research consultation.
Second Heart Assist, Inc. – Circulatory assist devices.

Cautionary Statement & Regulatory Status

Warning: Investigational Use Only. Not yet proven safe or effective in controlled clinical trials. Products described on this website are in early-stage development and are not yet proven safe or effective in statistically significant controlled clinical studies. Any statement or phrases implying efficacy or safety in any form are considered modified by “intended to” or “designed to”. NOT AVAILABLE FOR SALE. All use must be in an authorized clinical study with institutional review board (ethics committee) approval and proper patient consent.

/ A - Our Team

Our Team

Howard Leonhardt
Chairman of the Board & CEO
Howard J. Leonhardt, Chairman of the Board, Executive Chairman, Chief Technology Officer, MyoStim Pacers, Inc. Leonhardt also serves as Executive...
View details
Howard Leonhardt
Chairman of the Board & CEO
Howard J. Leonhardt, Chairman of the Board, Executive Chairman, Chief Technology Officer, MyoStim Pacers, Inc. Leonhardt also serves as Executive Chairman of Leonhardt Ventures a cardiovascular life science plus social good impact investment fund, angel network and innovation accelerator www.leonhardtventures.com. He is an inventor and serial entrepreneur with over 20 issued patents and numerous pending for products for treating cardiovascular and heart disease. His inventions have treated over 200,000 patients worldwide and have generated over $3 billion in revenues. His TALENT stent graft holds a world leading market share today as part of Medtronic Vascular. Leonhardt is the primary inventor of two of the three MyoStim Pacers pioneering patents along with Juan Chachques for utilizing electrical stimulation to recruit stem cells and differentiate them into heart muscle. He led the acquisition of the Kanno patent for utilizing electrical stimulation to stimulate new blood vessel formation. In 1983 Leonhardt was Export Sales Manager, and the first founding employee, of American General Medical Corporation in Hardeeville, SC that built and supplied cardiac cath labs and intensive care units in foreign markets. In late 1984 he joined International Marketing Advisors – Medical Group, Inc. in Fort Lauderdale, Florida as VP of International Sales. In early 1986 he founded World Medical Corporation a firm which helped manufacturers of cardiovascular devices to reach export markets. In 1988 he invented a series of improved cardiovascular balloon catheters and founded World Medical Manufacturing Corporation in Sunrise, Florida, that went on to develop over a dozen cardiovascular products including the TALENT stent graft for repairing aortic aneurysms without surgery, the first percutaneous heart valve, electrical stimulation devices for improving blood flow and the first stem cell delivery catheter systems, ProCell. The firm grew from just 2 employees to over 500 and merged with Arterial Vascular Engineering of Santa Rosa, California in April of 1998. In November of 1998 the combined firms were acquired by Medtronic, Inc. of Minneapolis, Minnesota. Leonhardt served as President & CEO of World Medical Mfg. Corp. from 1988 until June of 1999. From November 1998 to June 1999 he duly held the position of Vice President of Emerging New Therapies at Medtronic, Inc. In June 1999 Leonhardt founded Bioheart, Inc. with locations in both Florida and California with a focus on utilizing living stem cells for heart repair and personalized medicine. Bioheart introduced the first patented cardiovascular genetic test on the U.S. market in 2000. Leonhardt patented a biological pacemaker made entirely of living calls, and acquired the King patent, at Bioheart which is now the basis of the spin out company BioPace. He led Bioheart’s MyoCell into Phase II/III trial stage and the company is now in finalizing enrollment in its Phase III pivotal trial. Leonhardt served as Executive Chairman and CEO up to Bioheart’s IPO road show in 2007. In February 2008 following the NASDAQ IPO he moved full time to California to form his innovation accelerator with an initial focus on finding homes for Bioheart’s non-core spin out technologies. He has since served remotely as Chief Technology Officer, Chairman of the Scientific Advisory Board and as a member of the board of directors for Bioheart up to January 2013 where he shifted his focus entirely to serving MyoStim Pacers and his innovation accelerator in California. Leonhardt Ventures has raised and put to work $145 million in 28 innovation developments to date. Leonhardt serves on various boards including the Cell Therapy Foundation. He attends over 20 major cardiology meetings a year with an exhibit booth and side Technology Showcases highlighting MyoStim Pacers and other cardio innovations from his innovation accelerator and Leonhardt Ventures portfolio. He holds a diploma in International Trade from Anoka Technical College in Minneapolis and attended the University of Minnesota and Anoka Ramsey Community College. He has an honorary Doctorate in Biomedical Engineering from the University of Northern California, and is an honorary alumnus of both the University of Florida and Florida International University where he has been a substantial contributor to their entrepreneurship programs. He serves with the UCLA Bioengineering CE and UCLA Business of Science Center programs, as well as the USC Saben Research Institute, where he duly recruits talent to help advance forward Leonhardt Ventures innovations. In the spring of 2013 the Leonhardt Ventures innovation accelerator announced their partnership with the Alfred Mann spin out Core Manufacturing in Valencia, CA, where Leonhardt now has an office and laboratory, for advancing forward R&D and cGMP manufacturing of cardiovascular devices, including MyoStim Pacers.
Jeff Donofrio
Vice President
Jeff Donofrio has 25 years of Medical Sales and Sales management experience and has served as a senior consultant for...
View details
Jeff Donofrio
Vice President
Jeff Donofrio has 25 years of Medical Sales and Sales management experience and has served as a senior consultant for several CardioVascular companies. These include WL Gore & Associates, Edwards Lifesciences and Cardiac Assist, Inc. Jeff was the co-founder of Big Sky Medical Inc. which was built and successfully sold for a nice profit to a larger company. He has experience in building both direct sales forces as well as distribution networks.
Dr.,
Nicolas Chronos
Director Cardiovascular Research & Clinical Trial Design
Dr. Nicolas Chronos is an interventional cardiologist well known for his pioneering research in the treatment of heart disease. His...
View details
Dr.,
Nicolas Chronos
Director Cardiovascular Research & Clinical Trial Design
Dr. Nicolas Chronos is an interventional cardiologist well known for his pioneering research in the treatment of heart disease. His cardiology practice focuses on general cardiology, coronary artery disease management, and heart failure management. He is an expert in cardiac regenerative medicine, cardiovascular medical device assessment, and translational cardiovascular medicine.

Dr. Chronos established Cardiology Care Clinic at Lake Oconee in 2012 with his wife and cardiology physician’s assistant, Heather Chronos, to bring his modern approach to the treatment of heart disease to the lake community he cares about so deeply.
Dr.,
Jorge Genovese
Director of Electrical Stimulation Regenerative Therapies Research
Dr. Jorge Genovese serves as Vice-President of the Tissue Engineering Society International and as a member among other institutions, of...
View details
Dr.,
Jorge Genovese
Director of Electrical Stimulation Regenerative Therapies Research
Dr. Jorge Genovese serves as Vice-President of the Tissue Engineering Society International and as a member among other institutions, of the Latin American Biomaterials and Artificial Organs Society and a founding member of the Latin American Association of Tissues Banks. Dr. Genovese serves as Research Associate of Cardiac Stem Cells Therapies of the McGowan Institute program and as Research Professor of the Department of Surgery of the University of Pittsburgh Medical Center. Dr. Genovese has been devoted to different fields of tissue engineering including understanding how skeletal myoblasts might be used as a cell therapy for patients with heart disease. His research has also included testing the effects of electrical stimulation of myoblasts and adipose-derived stem cells prior to implantation. Dr. Genovese has been Member of Scientific Advisory Board at Bioheart, Inc. since January 17, 2007. He serves as Honorary President of the Tissue Engineering Committee of the National Academy of Science and Medicine of China. Dr. Genovese serves as a member of the editorial board of J. Stem Cells and the advisory board of Basic and Applied Myology. Dr. Genovese received his M.D. from the School of Medicine of Buenos Aires University, where he also obtained his Ph.D. after completing a thesis on TGF-Beta, an important growth factor involved in cell development and regeneration.
Dr.,
Stuart Williams
Co-Founder & Vice President R&D
Dr. Stuart Williams received his Ph.D. in cell biology from the University of Delaware, followed by postdoctoral training in pathology...
View details
Dr.,
Stuart Williams
Co-Founder & Vice President R&D
Dr. Stuart Williams received his Ph.D. in cell biology from the University of Delaware, followed by postdoctoral training in pathology at the Yale School of Medicine. During the period 1980 to 1990 he held a faculty appointment at Jefferson Medical College, where he was director of research in the department of surgery. In 1990 Dr. Williams joined the faculty at the University of Arizona and established the section of surgical research in the department of surgery. In 1997 he founded the University of Arizona biomedical engineering program, creating a research and educational link between the medical school and the college of engineering. He held faculty positions jointly in biomedical engineering, surgery, physiology and materials science and engineering.

Dr. Williams’ research interests have focused on medical devices, regenerative medicine and infection control. He developed and patented the first methods to use fat-derived stem cells for therapeutic use. He has maintained continuous funding from the National Institutes of Health since 1979.

Dr. Williams has authored over 300 scientific publications. His entrepreneurial spirit has resulted in 16 issued US patents with numerous patents pending. He has founded three biotechnology companies, maintained active managerial positions and has been an active consultant to the medical device and pharmaceutical community. He is a fellow of the American Heart Association and a fellow of the American Institute of Medical and Biological Engineering.
Brian Hardy
Marketing Communications
Mr. Hardy is a life long entrepreneur. Starting his first design and marketing company at the age of 18 in...
View details
Brian Hardy
Marketing Communications
Mr. Hardy is a life long entrepreneur. Starting his first design and marketing company at the age of 18 in Fort Lauderdale, Florida. He has founded many businesses over the years including a trade show exhibit house creating custom exhibits for clients such as the United States Army, M & I Bank, Interactive Toys and many others. From 2005-2008 he owned & operated a full service sign company, creating custom signs for companies like Ben & Jerry’s, Pita PIt, and Green Mountain Coffee. In 2008, he founded 4ColorFlyers.com. A fully-automated process allowing clients to track the progress of their print projects. 4 Color Flyers also does a wide variety of web design for clients such as LeonhardtVentures.com, CalStockExchange.com, HayleyBear.com, and LeonhardtVineyards.com. Mr. Hardy has over 13 years experience in graphic design, web design, and marketing industry.
Dr.,
Robert O. Becker
Consultant
In Fond Memory of Our Teacher
Author of the Body Electric
Consultant to Leonhardt Ventures 1985-87

View details
Dr.,
Robert O. Becker
Consultant
In Fond Memory of Our Teacher
Author of the Body Electric
Consultant to Leonhardt Ventures 1985-87
http://en.wikipedia.org/wiki/Robert_O._Becker
Tom Newman
Sales
Tom Newman has over twenty years of sales and sales management expertise working with well known companies such as Johnson...
View details
Tom Newman
Sales
Tom Newman has over twenty years of sales and sales management expertise working with well known companies such as Johnson & Johnson, Pfizer, and Biomet. Tom has built two medical distribution companies and also has served as a business development leader for two small startup companies.
Dr.,
Les Miller
Chief Medical Officer
Cardiologist. Former Chairman of Cardiovascular Medicine University of Minnesota. Author 240+ publications. Investigator in > 80 clinical trials. Editor leading...
View details
Dr.,
Les Miller
Chief Medical Officer
Cardiologist. Former Chairman of Cardiovascular Medicine University of Minnesota. Author 240+ publications. Investigator in > 80 clinical trials. Editor leading textbook on Stem Cell Therapies for Cardiovascular & Heart Disease.

1982-1996 Saint Louis University: Assistant Professor Medicine and Surgery;
1982-1996: Director of the Coronary Care Unit
1986-1989: Associate Professor of Medicine and Surgery; Director of the Heart Transplant and Mechanical Support Program
1989-1996: Professor of Medicine and Surgery

1996-1997: Sabbatical leave: University of Alberta, CA with Dr Phiillp Halloran focused in immunology and immunosuppression, and Dr Alexandra Lucas on vascular biology

1997-2007: Professor and Chair of the Division of Cardiology, Univ of Minnesota;
Director of the Heart Transplant and Mechanical Assist Program, and
Director of the Cardiology Fellowship Program

2005-2007: Founding Director of the Lillehei Heart Institute, U of MN

2007-2010: Chair of the combined Division of Cardiology Georgetown University
and Washington Hospital Center
Proctor Harvey Distinguished Professor of Cardiology, Georgetown Univ
Director of the Heart Transplant and Mechanical Support Program
Director of the Cardiology Fellowship Program

2010-2013: Chairman the Department of Cardiology Univ South Florida
Edward C. Wright Professor of Cardiovascular Medicine
Director of the Cardiology Fellowship Program

2012-2013: Director of the Cardiovascular Institute

2013-2016: Director of Heart Failure Morton Plant Hospital

2016-current: Chief Medical Officer, Leonhardt Ventures

1988-2009: Founder and Chair: Working Group of Transplant Cardiologists

1995-1997: President of American Society of Transplant Physicians

1997-1998: President of International Society of Heart and Lung Transplantation

1999: Citation of Merit: University of Missouri, Outstanding Alumnus

1999-2006: Board of Directors of Cardiovascular Translational Research Society

2014- : Chairman of the Board of the Alliance for the Advancement of Stem Cell Research

2013- : Board of Directors International Congress of Cardiology
Dr.,
Robert Kellar
Advisor Infarction Healing

Dr. Kellar is the Founder and President of AxoLotl Biologics and Development Engineering...
View details
Dr.,
Robert Kellar
Advisor Infarction Healing

Dr. Kellar is the Founder and President of AxoLotl Biologics and Development Engineering Sciences, LLC, a biomedical consulting firm. He has over 15 years of experience in the development and regulatory approval of medical devices, cell-based products, and tissue engineered technology. Previously, Dr. Kellar was VP of Research and Development at Histogen, Inc. where he led multi-functional project teams for all aspects of product development. Prior to Histogen, Dr. Kellar was a product specialist for the first FDA-approved thoracic endograft at W.L. Gore and Associates where he served a lead role in development, regulatory, clinical trials, marketing, sales, and business for the thoracic device and the product portfolio. Previous to this position, Dr. Kellar was a product specialist for the Global Oral Health Business at W.L. Gore & Associates (both Gore-Tex® Regenerative Membranes and the entire resorbable membrane portfolio). Prior to Gore, at Advanced Tissue Sciences, Inc. he led cardiovascular research programs and managed the Anginera® program. Dr. Kellar previously served on the Scientific Advisory Board for Theregen, currently serves on the Scientific Advisory Board for MyoStim, and is on the Faculty in Biological Sciences and Mechanical Engineering at Northern Arizona University. Dr. Kellar also serves on the Board of Directors for the Surfaces in Biomaterials Foundation and Flagship Biosciences, a digital pathology company. He serves as an Advisory Board Member for Protein Genomics, a protein polymer medical device company. He earned his Ph.D. in Physiological Sciences from the University of Arizona.
Jeremy Koff
VP Business Development
Jeremy Koff has over 25 years experience in the medical device industry most of those years with Alfred Mann Companies...
View details
Jeremy Koff
VP Business Development
Jeremy Koff has over 25 years experience in the medical device industry most of those years with Alfred Mann Companies including Advanced Bionics. He currently serves as a consultant with a focus in the bioelectric and neuro modulation sectors. Jeremy Koff is the nephew of the legendary Los Angeles biomedical industry pioneer Alfred Mann.
Dr.,
Mark Cunningham
Chief Advisor CardioThoracic Surgery
Dr. Mark Cunningham is a degreed engineer as well as a physician, scientist, business manager and entrepreneur. He is Chief...
View details
Dr.,
Mark Cunningham
Chief Advisor CardioThoracic Surgery
Dr. Mark Cunningham is a degreed engineer as well as a physician, scientist, business manager and entrepreneur. He is Chief of Mechanical Circulatory Assist Support and at USC Keck Cardio-Thoracic Surgery Department and Former Chief of Staff of USC Keck.

/ – THE TECHNOLOGY

The Technology behind it

Discover the science and innovation driving our advanced solutions, designed to deliver safe, effective, and transformative results.

Bioelectric Stimulation for Heart Regeneration

Our core technology utilizes a Quarter-size micro implant stimulator, typically implanted in the chest or abdomen like a traditional pacemaker.

Integration: Bioelectric heart regeneration programs can be loaded into standard CRT/ICD pacers.
Delivery: 1st generation uses one lead to the center of the myocardial scar. Future iterations utilize non-invasive temporal interference technologies.

Patented & Patent-Pending Bioelectric Signals and Sequences

We utilize precise sequences for the controlled release of regeneration-promoting proteins and real-time inflammation management:

SDF-1: Stem cell homing signal.
IGF-1: DNA repair and regeneration.
HGF / EGF / PDGF: Regeneration and stem cell homing.
VEGF / CCXL5 / HIF1a: New and mature blood vessel growth (Angiogenesis).
eNOS: Blood vessel dilatation.
Follistatin: Muscle regeneration (the most powerful protein for recovery).
Tropoelastin: Increasing tissue elasticity in the heart muscle and arteries.
ILs: Real-time inflammation reading and management.
GDF-10 & 11 / Activin A+B: Cellular regeneration.
Stem Cell Proliferation & Differentiation: Transforming cells into beating, pumping muscle.
Blood Pressure Management: Post-regeneration hemodynamic control.

Micro Infusion Pump

The second pillar of our platform is a high-precision micro-infusion pump, tested and developed over the last 5 years with over $2 million in NSF Small Business Innovation Research (SBIR) grant support.

Function: Provides precise, slow-infusion delivery of our heart regeneration composition directly to the targeted site.
Frequency: Enables repeat daily, weekly, or monthly deliveries, which we believe is essential for cell retention and survival.

BL-15 Heart Regeneration Composition

The BL-15 is a sophisticated, fifteen-component mixed stem cell-based composition designed to provide the heart with everything it needs to rebuild. Composition components:

Stem Cells & Immature Myoblasts: The cellular foundation for new muscle.
Selected Exosomes & Micro RNAs: For cellular communication and repair instructions.
Amniotic Fluid: Chock full of over 200 growth factors.
Platelet Rich Fibrin (PRF): Providing slow-release growth factors.
Selected Alkaloids: Such as tetraharmine.
Nutrient Engineered Hydrogel: To improve cell survival and retention.
Growth Factors: Including Follistatin, Tropoelastin, IGF-1, and PDGF.
Heart Matrix: Providing the structural scaffold for new tissue growth.

The Biological Mechanism: Transforming Scar Tissue into Muscle

Our platform does more than just supply cells; it “instructs” them through a sophisticated bio-electric micro-environment. BioLeonhardt utilizes patented bioelectric signals designed to govern the three critical phases of regeneration: Homing (recruiting stem cells to the site of injury), Proliferation (stimulating cellular growth), and Differentiation (programming immature myoblasts to become functional, beating heart muscle).

This synergy is powered by the BL-15 composition, which integrates selected exosomes, microRNAs, and nutrient-engineered hydrogels. Together, these components work to reverse remodeling in the failing heart, effectively converting rigid, non-functional fibrotic scar tissue into elastic, pumping muscle. This process mimics the natural embryonic development of heart tissue to achieve total cardiac recovery.

University of Utah Partnership: Validating Protein Expression

The credibility of BioLeonhardt technology is anchored in rigorous, university-level scientific research. A landmark study conducted in collaboration with the University of Utah Department of Bioengineering has statistically validated the efficacy of our signaling platform. The data demonstrates that our specific bioelectric sequences can stimulate a 400% increase in Vascular Endothelial Growth Factor (VEGF) mRNA expression.

VEGF is the essential protein responsible for Angiogenesis—the growth of new, healthy blood vessels. As the heart muscle regenerates, it requires an increased supply of oxygen and nutrients to survive. Our system bioelectrically ensures this vascular support is present, sustaining the heart through the entire 36-month regeneration course. This research poster serves as a definitive biological proof-of-concept for our “Signals + Biologics” approach.

/ – KNOWLEDGE BASE

Related resources

Want to learn more? Browse our clinical resources and scientific publications on our comprehensive suite of targeted treatments.

Strategic Presentations & Investor Intelligence

This section provides a high-level overview of BioLeonhardt’s business model, investment potential, and clinical roadmap for stakeholders.

BioLeonhardt Core Strategy Presentation

A comprehensive visual pitch deck covering the market need, technology synergy, and global business milestones for the heart regeneration platform.

BioLeonhardt

Get in touch

About this Venture

Corporate Mission & Philosophy

Bioelectric Innovation: Reversing Fibrosis

Unmatched Research Team Experience

Total Regeneration Platform Strategy

The Ultimate Team Alliance: All-Star Partners

Cautionary Statement & Regulatory Status

Our Team

Howard Leonhardt

Howard Leonhardt

Jeff Donofrio

Jeff Donofrio

Dr.,

Nicolas Chronos

Dr.,

Nicolas Chronos

Dr.,

Jorge Genovese

Dr.,

Jorge Genovese

Dr.,

Stuart Williams

Dr.,

Stuart Williams

Brian Hardy

Brian Hardy

Dr.,

Robert O. Becker

Dr.,

Robert O. Becker

Tom Newman

Tom Newman

Dr.,

Les Miller

Dr.,

Les Miller

Dr.,

Robert Kellar

Dr.,

Robert Kellar

Jeremy Koff

Jeremy Koff

Dr.,

Mark Cunningham

Dr.,

Mark Cunningham

The Technology behind it

Bioelectric Stimulation for Heart Regeneration

Patented & Patent-Pending Bioelectric Signals and Sequences

Micro Infusion Pump

BL-15 Heart Regeneration Composition

The Biological Mechanism: Transforming Scar Tissue into Muscle

University of Utah Partnership: Validating Protein Expression

Related resources

Strategic Presentations & Investor Intelligence

BioLeonhardt Core Strategy Presentation

Heart Regeneration Technology Deck

BioLeonhardt Executive Summary (2022)

Pre-Clinical Cardiac Regeneration Study Protocol

Patents, Hardware & Scientific Evidence

Leonhardt Implantable MicroStimulator Option II

Triple-Component Therapy Platform Patent

Bioelectric Controlled Expression of Follistatin Patent

Bioelectric Expression of PDGF Patent Filing

Leonhardt HIF-1 Alpha Estate Addition

Myogenic Specification of Side Population Cells

Angiogenic Potential of Adipose Stem Cells

VEGF and PDGF Improved Cardiac Function

Induction of Myogenic Differentiation by SDF-1

Alignment of Muscle Cells in Collagen Gel:

Myogenic Differentiation of Mesenchymal Stem Cells

IGF-1 Overexpression Rescues Failing Hearts

New Insights into IGF-1 Signaling

IGF Signaling in Zebrafish Heart Regeneration

IGF-1 Receptor Identifying Cardiac Stem Cells

VEGF Effect on Adipose Stem Cell Differentiation

Sonic Hedgehog Signaling in Cardiac Response

MicroRNA Transfer via Gap Junction Connectivity